Under construction – not a live service
Sign in
Taking people in United StatesPhase 3

Compares lymph node mapping with standard removal in early womb cancer

Tests a dye-guided lymph node check against standard removal in women with early endometrial cancer.

Plain-language title generated from the registry record
Registry title: Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

Key facts

Where
Augusta, Baltimore, Bel Air, Billings, Bryn Mawr, Butte, Carmel, Charlottesville, Chicago, Coral Gables, Dallas, Deerfield Beach, Detroit, Doral, Edina, Farmington Hills, Flint, Fort Worth, Houston, Indianapolis, Kearney, Las Vegas, Maple Grove, Maplewood, Marrero, Metairie, Miami, New Orleans, North Miami, Oklahoma City, Omaha, Paoli, Plantation, Princeton, Providence, Richardson, Saint Paul, Springfield, Sugar Land, The Woodlands, Warrenville, Washington D.C., Wynnewood, and Wyoming, United StatesSee the 55 sites
Phase
Phase 3

Where in United States

  • Augusta University Medical CenterAugusta, United StatesTaking people
  • University of Maryland/Greenebaum Cancer CenterBaltimore, United StatesTaking people
  • UM Upper Chesapeake Medical CenterBel Air, United StatesTaking people
  • Intermountain Health West End ClinicBillings, United StatesNo longer taking part
  • Saint Vincent Frontier Cancer CenterBillings, United StatesNo longer taking part
  • Saint Vincent HealthcareBillings, United StatesNo longer taking part
  • Bryn Mawr HospitalBryn Mawr, United StatesNo longer taking part
  • Saint James Community Hospital and Cancer Treatment CenterButte, United StatesNo longer taking part
  • IU Health North HospitalCarmel, United StatesTaking people
  • University of Virginia Cancer CenterCharlottesville, United StatesTaking people
  • Northwestern UniversityChicago, United StatesTaking people
  • UM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables, United StatesTaking people
  • Parkland Memorial HospitalDallas, United StatesTaking people
  • UT Southwestern/Simmons Cancer Center-DallasDallas, United StatesTaking people
  • UM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach, United StatesTaking people
  • Wayne State University/Karmanos Cancer InstituteDetroit, United StatesTaking people
  • UM Sylvester Comprehensive Cancer Center at DoralDoral, United StatesTaking people
  • Fairview Southdale HospitalEdina, United StatesTaking people
  • Weisberg Cancer Treatment CenterFarmington Hills, United StatesTaking people
  • McLaren Cancer Institute-FlintFlint, United StatesTaking people
  • UT Southwestern/Simmons Cancer Center-Fort WorthFort Worth, United StatesTaking people
  • Memorial Hermann Texas Medical CenterHouston, United StatesTaking people
  • Houston Methodist HospitalHouston, United StatesNo longer taking part
  • Houston Methodist West HospitalHouston, United StatesNo longer taking part
  • Methodist Willowbrook HospitalHouston, United StatesNo longer taking part
  • Indiana University/Melvin and Bren Simon Cancer CenterIndianapolis, United StatesTaking people
  • Fred and Pamela Buffett Cancer Center - KearneyKearney, United StatesTaking people
  • Women's Cancer Center of NevadaLas Vegas, United StatesTaking people
  • Fairview Clinics and Surgery Center Maple GroveMaple Grove, United StatesTaking people
  • Saint John's Hospital - HealtheastMaplewood, United StatesTaking people
  • West Jefferson Medical CenterMarrero, United StatesTaking people
  • East Jefferson General HospitalMetairie, United StatesTaking people
  • LSU Healthcare Network / Metairie Multi-Specialty ClinicMetairie, United StatesTaking people
  • UM Sylvester Comprehensive Cancer Center at KendallMiami, United StatesTaking people
  • University of Miami Miller School of Medicine-Sylvester Cancer CenterMiami, United StatesTaking people
  • Louisiana State University Health Science CenterNew Orleans, United StatesTaking people
  • University Medical Center New OrleansNew Orleans, United StatesTaking people
  • University of Miami Sylvester Comprehensive Cancer Center at Sole MiaNorth Miami, United StatesTaking people
  • University of Oklahoma Health Sciences CenterOklahoma City, United StatesTaking people
  • Nebraska Medicine-Village PointeOmaha, United StatesTaking people
  • University of Nebraska Medical CenterOmaha, United StatesTaking people
  • Alegent Health Bergan Mercy Medical CenterOmaha, United StatesNo longer taking part
  • Paoli Memorial HospitalPaoli, United StatesNo longer taking part
  • UM Sylvester Comprehensive Cancer Center at PlantationPlantation, United StatesTaking people
  • Fairview Northland Medical CenterPrinceton, United StatesTaking people
  • Women and Infants HospitalProvidence, United StatesTaking people
  • UT Southwestern Clinical Center at Richardson/PlanoRichardson, United StatesTaking people
  • Regions HospitalSaint Paul, United StatesTaking people
  • Mercy Hospital SpringfieldSpringfield, United StatesTaking people
  • Houston Methodist Sugar Land HospitalSugar Land, United StatesNo longer taking part
  • Houston Methodist The Woodlands HospitalThe Woodlands, United StatesNo longer taking part
  • Northwestern Medicine Cancer Center WarrenvilleWarrenville, United StatesTaking people
  • George Washington University Medical CenterWashington D.C., United StatesNo longer taking part
  • Lankenau Medical CenterWynnewood, United StatesNo longer taking part
  • Fairview Lakes Medical CenterWyoming, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
NRG Oncology
Trial code
NCT05646316
Record updated
6 November 2026
Original description
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Standard lymph node dissection removes lymph nodes around the uterus during a hysterectomy to look for spread of cancer from the uterus to nearby lymph nodes. Sentinel lymph node mapping uses a special dye and camera to look for cancer that may have spread to nearby lymph nodes. Comparing the results of the procedures may help doctors predict the risk of long-term swelling in the legs.Read full original descriptionShow less

A Phase III Trial Of The Impact Of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction In Endometrial Cancer

This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Standard lymph node dissection removes lymph nodes around the uterus during a hysterectomy to look for spread of cancer from the uterus to nearby lymph nodes. Sentinel lymph node mapping uses a special dye and camera to look for cancer that may have spread to nearby lymph nodes. Comparing the results of the procedures may help doctors predict the risk of long-term swelling in the legs.

Inclusion: Histologically proven diagnosis of endometrial cancer based on endometrial sampling with a plan to undergo laparoscopic or robotic hysterectomy and lymphatic assessment as part of primary management. Biopsy must be performed within 90 days prior to registration; Clinical stage I endometrial cancer based on the following diagnostic workup:; History/physical examination within 30 days prior to registration is reassuring for the absence of metastatic disease; Age >= 18 years; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2; Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial; The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information; Patients must speak English, Spanish, or Korean.

Exclusion: Patients whom the surgeon believes is not a candidate for pelvic lymphadenectomy due to medical comorbidities or other technical challenges (i.e. morbid obesity or prior surgery); Patients who are going to undergo another elective surgery during the same operative event as their hysterectomy (i.e., sacrocolpopexy, cholecystectomy); History of chemotherapy or immunotherapy for the treatment of endometrial cancer. Progestin-containing therapies such as megestrol, medroxyprogesterone, or levonorgestrel-containing intrauterine device (IUD) are acceptable; History of radiation to the pelvis, groin or lower extremities, or surgery to the pelvic lymph nodes or inguinal lymph nodes; Patients with severe, active co-morbidity defined as follows:; History of patient or provider identified lower extremity lymphedema; History of patient or provider identified chronic lower extremity swelling; History of lower extremity or pelvic deep venous thromboembolism within 90 days of registration; History of lower extremity cellulitis within 90 days of registration.

ClinicalTrials.gov NCT05646316